PIK3CA mutation subtype delineates distinct immune profiles in gastric carcinoma
The Journal of Pathology · 2023
DOI: 10.1002/path.6134 ↗At a glance
Journal article in The Journal of Pathology, 2023. Written by Sangjoon Choi and 6 co-authors. Institution: Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Major MEDLINE topics: Epstein-Barr Virus Infections, Stomach Neoplasms, Carcinoma. Cited 13 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
PIK3CA mutations in cancer regulate tumour immunogenicity. Given that PIK3CA mutation subtypes influence therapeutic responses to AKT inhibitor and that H1047R mutation confers selective growth advantages after immunotherapy, we hypothesised that immune phenotypes may depend on PIK3CA mutation subtypes. We investigated 133 gastric cancers (GCs) harbouring PIK3CA mutation [21 E542K (15.8%), 36 E545X (27.1%), 26 H1047X (19.5%), and 46 others (34.6%)]. Four patients (3.0%) had a combination of mutations (E542K + E545K in 3 patients and E545K + H1047R in 1 patient). Epstein–Barr virus (EBV) and microsatellite instability (MSI) status, PD‐L1 (programmed death‐ligand 1) combined positive score (CPS), and stromal tumour‐infiltrating lymphocytes (TILs) were assessed. Concurrent genomic alterations, GeoMx digital spatial profiling (DSP), and OPAL multiplex immunohistochemistry (mIHC) were analysed, and correlation between the two assays was investigated. Of the 133 PIK3CA ‐mutant ( PIK3CA m ) GCs, MSI‐high GC was significantly frequent in the H1047X mutation subtype ( p = 0.005), while EBV positivity did not affect the mutation subtypes. There was no significant survival difference between the E542K, E545X, and H1047X subgroups. However, in the subgroup analysis for EBV‐positive GC, H1047X m GC showed a trend towards shorter survival than E542K and E545X m GC ( p = 0.090 and 0.062). With DSP analysis, H1047X m GC showed elevated VISTA ( p = 0.0003), granzyme B ( p < 0.0001), CD4 ( p = 0.0001), and CD45 ( p < 0.0001) expression compared with the E542K m or E545X m GC subgroups, and only VISTA expression remained significant ( p < 0.0001) using OPAL mIHC. DSP and OPAL analyses showed a moderate correlation of CD4 ( ρ = 0.42, p = 0.004) and CD8 ( ρ = 0.62, p < 0.001) expression levels in a comparison of six antibodies. Immune‐related protein expression levels were evident when classified by the three PIK3CA hotspot mutations, and H1047X m GC showed the highest immune‐related protein expression compared with E542K m or E545X m GC. Our results demonstrated distinct immune profiles in GC with PIK3CA hotspot mutations using GeoMx DSP and OPAL mIHC, and there was a correlation between the two multiplex platforms. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Pathology Center, Seegene Medical Foundation, Seoul, Republic of Korea.
- The Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Center of Companion Diagnostics, Samsung Medical Center, Seoul, Republic of Korea.
- Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
ORCID profiles: So Young Kang, Kyoung-Mee Kim
Cite
APA
Choi, S., Kim, H., Heo, Y. J., Kang, S. Y., Ahn, S., Lee, J., & Kim, K. M. (2023). PIK3CA mutation subtype delineates distinct immune profiles in gastric carcinoma. The Journal of Pathology. https://doi.org/10.1002/path.6134
Vancouver
Choi S, Kim H, Heo YJ, Kang SY, Ahn S, Lee J, et al. PIK3CA mutation subtype delineates distinct immune profiles in gastric carcinoma. The Journal of Pathology. 2023. doi:10.1002/path.6134
BibTeX
@article{Choi2023,
author = {Choi, Sangjoon and Kim, Hyunjin and Heo, You Jeoung and Kang, So Young and Ahn, Soomin and Lee, Jeeyun and Kim, Kyoung-Mee},
title = {PIK3CA mutation subtype delineates distinct immune profiles in gastric carcinoma},
journal = {The Journal of Pathology},
year = {2023},
doi = {10.1002/path.6134}
}
EUVIMED